Interdependent Metabolic Processes Driving Non-Hodgkin's

According to a new paper by a research team from UNC Lineberger Comprehensive Cancer Center and appearing in the prestigious Proceedings of the National Academy of Sciences, a new breakthrough has been discovered regarding targeted treatments for non-Hodgkin's lymphoma.

The researchers determined that two inter-related metabolic processes are together responsible for the cell proliferation in NHLs.

A cell signaling pathway known as PI3K/AKT/mTOR becomes activated in a number of subtypes of B-cell non-Hodgkin lymphoma. This same pathway is also crucial in controlling cell metabolism, notably how cells use sugar in a process called aerobic glycolysis.

“Our team found evidence that glycolysis and fatty acid synthesis are interdependent in B-cell non-Hodgkin lymphoma," said Blossom Damania, PhD. "The good news is that the lymphoma cells are much more sensitive to a compound that inhibits fatty acid synthesis, as compared to normal B cells. This suggests that fatty acid synthase, the enzyme that drives fatty acid synthesis, is a promising target for new therapies against lymphoma,"

This broadened understanding of cell metabolism could lead to new therapeutic targets in the treatment of B-cell non-Hodgkin's lymphomas.

Source: UNC Health Care

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap